Company Encyclopedia
View More
name
InspireMD
NSPR.US
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions. It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners.
325.40 B
NSPR.USMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking27/42
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-87.61%E
    • Profit Margin-593.89%E
    • Gross Margin34.24%C
  • Growth ScoreB
    • Revenue YoY14.04%B
    • Net Profit YoY-63.62%D
    • Total Assets YoY55.45%A
    • Net Assets YoY55.05%A
  • Cash ScoreC
    • Cash Flow Margin-16.84%D
    • OCF YoY14.04%B
  • Operating ScoreE
    • Turnover0.12E
  • Debt ScoreA
    • Gearing Ratio18.30%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference | NSPR Stock News

    InspireMD, Inc. (Nasdaq: NSPR) announced its participation in the Piper Sandler 37th Annual Healthcare Conference on December 3rd, 2025. The company will engage in a fireside discussion, accessible via live audio webcast and replay on its website. InspireMD aims to establish its MicroNet™ mesh technology as the industry standard for carotid stenting. For more information, visit their website or contact their investor relations.

    StockTitan·
    US
    NSPR
    +13.53%
    StockTitan·
    US
    NSPR
    +13.53%

    Director Makes Bold Move with Major Stock Purchase in InspireMD

    Director Paul Stuka purchased 13,431 shares of InspireMD (NSPR) stock, valued at $21,758, indicating confidence in the company's future. InspireMD reported a 39% revenue increase for Q3 2025, driven by the U.S. launch of its CGuard Prime carotid stent system, but faced a net loss of $12.7 million. Despite financial challenges, the company remains optimistic with $58 million in gross proceeds and strategic advancements. Analysts, however, note ongoing losses and valuation issues, rating the stock as Neutral.

    Tip Ranks·
    US
    NSPR
    +13.53%
    Tip Ranks·
    US
    NSPR
    +13.53%

    InspireMD | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 2.523 M

    LB filings·
    US
    NSPR
    +13.53%
    LB filings·
    US
    NSPR
    +13.53%

    InspireMD Inc’s Earnings Call: Growth Amid Challenges

    InspireMD Inc's earnings call revealed robust growth despite financial challenges. The company reported a 39% year-over-year revenue increase to $2.5 million in Q3 2025, driven by the U.S. launch of CGuard Prime and strong international performance. Operating expenses rose to $13.9 million, leading to a net loss of $12.7 million. However, gross profit more than doubled, and cash reserves reached $63.4 million. Looking ahead, InspireMD expects Q4 revenue between $2.5 million and $3.0 million, supported by ongoing U.S. sales and international demand.

    Tip Ranks·
    US
    NSPR
    +13.53%
    Tip Ranks·
    US
    NSPR
    +13.53%

    InspireMD Reports Record Q3 Revenue with U.S. Launch

    InspireMD reported record Q3 revenue of $2.5 million, a 39% increase year-over-year, following the U.S. launch of its CGuard Prime carotid stent system. The company completed over 100 procedures but faced a net loss of $12.7 million. Despite financial challenges, it raised $58 million in July and received a Buy rating from analysts with a $5.00 price target. However, Spark's AI Analyst rates NSPR as Neutral due to ongoing profitability issues and a bearish technical outlook. InspireMD focuses on stroke prevention with its proprietary technology and is listed on Nasdaq under NSPR.

    Tip Ranks·
    US
    NSPR
    +13.53%
    Tip Ranks·
    US
    NSPR
    +13.53%